<!DOCTYPE html>
<html lang="en">
<head>
 <meta charset="UTF-8">
 <meta name="viewport" content="width=device-width, initial-scale=1.0">
 <title>Lesson 2: The Window of Opportunity Hypothesis & Cardiovascular Data | AccrediPro Academy</title>
 <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700;800&display=swap" rel="stylesheet">
 <style>
/* ===========================================
 ACCREDIPRO GOLD STANDARD - UNIFIED LESSON CSS v5.0
 School-Quality ‚Ä¢ ASI Certified ‚Ä¢ Premium UX
 =========================================== */

/* Reset & Base */
* {
 box-sizing: border-box;
 margin: 0;
 padding: 0;
}

body {
 font-family: 'Inter', -apple-system, BlinkMacSystemFont, sans-serif;
 line-height: 1.8;
 color: #1f2937;
 background: #ffffff;
 font-size: 17px;
}

/* MAIN WRAPPER */
.lesson-wrapper {
 max-width: 1200px;
 margin: 0 auto;
 padding: 40px 20px;
}

/* HEADER CARD - Premium Gradient */
.module-header-card {
 background: linear-gradient(135deg, #722F37 0%, #722F37 50%, #5a252b 100%);
 padding: 48px 40px;
 margin-bottom: 40px;
 border-radius: 24px;
 box-shadow: 0 20px 60px -15px rgba(114, 47, 55, 0.4);
 border: none;
 text-align: center;
 position: relative;
 overflow: hidden;
}

.module-header-card::before {
 content: '';
 position: absolute;
 top: -50%;
 left: -50%;
 width: 200%;
 height: 200%;
 background: radial-gradient(circle, rgba(255, 255, 255, 0.05) 0%, transparent 70%);
 pointer-events: none;
}

.module-label {
 font-size: 12px;
 text-transform: uppercase;
 letter-spacing: 3px;
 color: rgba(255, 255, 255, 0.8);
 margin-bottom: 12px;
 font-weight: 600;
 display: block;
}

.lesson-title {
 font-size: 38px;
 color: #ffffff;
 font-weight: 800;
 margin: 0 0 20px 0;
 line-height: 1.15;
 text-shadow: 0 2px 4px rgba(0, 0, 0, 0.1);
}

/* META BADGES */
.lesson-meta {
 display: flex;
 justify-content: center;
 gap: 12px;
 flex-wrap: wrap;
}

.meta-badge {
 background: rgba(255, 255, 255, 0.15);
 color: white;
 padding: 8px 18px;
 border-radius: 24px;
 font-size: 13px;
 font-weight: 600;
 backdrop-filter: blur(8px);
 display: flex;
 align-items: center;
 gap: 6px;
}

/* ASI CREDENTIAL STRIP */
.asi-credential-strip {
 background: linear-gradient(90deg, #f8f5f0, #fffbeb, #f8f5f0);
 border: 1px solid #e5d9c3;
 border-radius: 12px;
 padding: 16px 24px;
 margin-bottom: 32px;
 display: flex;
 align-items: center;
 gap: 16px;
}

.asi-logo {
 width: 48px;
 height: 48px;
 background: linear-gradient(135deg, #B8860B, #D4A813);
 border-radius: 10px;
 display: flex;
 align-items: center;
 justify-content: center;
 font-size: 24px;
 color: white;
 flex-shrink: 0;
 box-shadow: 0 4px 12px rgba(184, 134, 11, 0.25);
}

.asi-text {
 flex: 1;
}

.asi-text .label {
 font-size: 11px;
 text-transform: uppercase;
 letter-spacing: 1px;
 color: #92400e;
 font-weight: 700;
}

.asi-text .title {
 font-size: 15px;
 color: #78350f;
 font-weight: 600;
 margin-top: 2px;
}

/* TABLE OF CONTENTS */
.toc-box {
 background: transparent;
 border: none;
 border-radius: 0;
 padding: 0;
 margin-bottom: 40px;
}

.toc-label {
 font-size: 11px;
 text-transform: uppercase;
 letter-spacing: 1.5px;
 color: #6b7280;
 font-weight: 700;
 margin-bottom: 16px;
 display: block;
}

.toc-list {
 list-style: none;
 display: grid;
 grid-template-columns: repeat(auto-fit, minmax(200px, 1fr));
 gap: 8px;
}

.toc-list li a {
 display: flex;
 align-items: center;
 gap: 10px;
 padding: 10px 14px;
 background: #f9fafb;
 border: none;
 border-radius: 8px;
 text-decoration: none;
 color: #374151;
 font-size: 14px;
 font-weight: 500;
 transition: all 0.2s;
}

.toc-list li a:hover {
 background: #f3f4f6;
 color: #722F37;
 transform: translateX(4px);
}

.section-num {
 background: #722F37;
 color: white;
 width: 24px;
 height: 24px;
 border-radius: 6px;
 display: flex;
 align-items: center;
 justify-content: center;
 font-size: 11px;
 font-weight: 700;
 flex-shrink: 0;
}

/* WELCOME BOX */
.welcome-box {
 background: linear-gradient(135deg, #fefbf3 0%, #f8f5f0 100%);
 padding: 28px;
 margin-bottom: 40px;
 border-radius: 16px;
 border-left: 5px solid #B8860B;
 box-shadow: 0 4px 12px rgba(0, 0, 0, 0.04);
}

.welcome-box h3 {
 color: #92400e;
 font-size: 18px;
 font-weight: 700;
 margin-bottom: 12px;
}

.welcome-box p {
 margin: 0;
 font-size: 16px;
 color: #44403c;
 line-height: 1.7;
}

/* OBJECTIVES BOX */
.objectives-box {
 background: linear-gradient(135deg, #faf5ff 0%, #f3e8ff 100%);
 border-radius: 16px;
 padding: 28px;
 margin-bottom: 40px;
 border: 1px solid #e9d5ff;
}

.box-label {
 font-weight: 700;
 color: #7e22ce;
 text-transform: uppercase;
 letter-spacing: 1px;
 font-size: 12px;
 margin-bottom: 16px;
 display: block;
}

.objectives-box ul {
 list-style: none;
 margin: 0;
 padding: 0;
}

.objectives-box li {
 padding: 10px 0 10px 32px;
 position: relative;
 font-size: 16px;
 color: #4c1d95;
 border-bottom: 1px solid rgba(167, 139, 250, 0.2);
}

.objectives-box li::before {
 content: '‚úì';
 position: absolute;
 left: 0;
 color: #7c3aed;
 font-weight: 700;
}

/* HIGHLIGHT */
.highlight {
 background: linear-gradient(120deg, #fef3c7 0%, #fef3c7 100%);
 padding: 1px 4px;
 border-radius: 4px;
 font-weight: 600;
 color: inherit;
}

/* TYPOGRAPHY */
h2 {
 color: #722F37;
 font-size: 28px;
 margin: 56px 0 24px 0;
 font-weight: 800;
 position: relative;
 padding-bottom: 16px;
}

h2::after {
 content: '';
 position: absolute;
 bottom: 0;
 left: 0;
 width: 60px;
 height: 4px;
 background: linear-gradient(90deg, #B8860B, #D4A813);
 border-radius: 2px;
}

h3 {
 color: #722F37;
 font-size: 22px;
 margin: 36px 0 16px 0;
 font-weight: 700;
}

p {
 font-size: 17px;
 line-height: 1.85;
 color: #374151;
 margin-bottom: 20px;
}

/* DATA TABLE */
.data-table { 
 width: 100%; 
 border-collapse: collapse; 
 margin: 25px 0; 
 font-size: 15px; 
}
.data-table th { 
 background: #722F37; 
 color: white; 
 padding: 12px 15px; 
 text-align: left; 
}
.data-table td { 
 padding: 12px 15px; 
 border-bottom: 1px solid #e5e7eb; 
}
.data-table tr:nth-child(even) { 
 background: #f9fafb; 
}

/* CASE STUDY */
.case-study {
 background: white;
 border-radius: 20px;
 margin: 40px 0;
 border: 1px solid #e5e7eb;
 box-shadow: 0 8px 30px rgba(0, 0, 0, 0.06);
 overflow: hidden;
}

.case-study-header {
 background: linear-gradient(90deg, #722F37, #722F37);
 padding: 20px 28px;
 display: flex;
 align-items: center;
 gap: 16px;
}

.case-study-icon {
 width: 48px;
 height: 48px;
 background: rgba(255, 255, 255, 0.2);
 border-radius: 12px;
 display: flex;
 align-items: center;
 justify-content: center;
 font-size: 24px;
}

.case-study-header .title {
 color: white;
 font-weight: 700;
 font-size: 16px;
 margin: 0;
}

.case-study-content {
 padding: 28px;
}

/* COACH TIP BOX */
.coach-tip {
 background: linear-gradient(135deg, #fefce8 0%, #fef9c3 100%);
 border: 1px solid #fde047;
 border-radius: 16px;
 padding: 24px 28px;
 margin: 32px 0;
 position: relative;
}

.coach-tip::before {
 content: 'üí°';
 position: absolute;
 top: -12px;
 left: 24px;
 background: white;
 padding: 4px 8px;
 border-radius: 8px;
 font-size: 20px;
 box-shadow: 0 2px 8px rgba(0,0,0,0.08);
}

.coach-tip .tip-label {
 font-size: 11px;
 text-transform: uppercase;
 letter-spacing: 1.5px;
 color: #a16207;
 font-weight: 700;
 margin-bottom: 8px;
 display: block;
}

/* MODULE CONNECTION BOX */
.module-connection {
 background: linear-gradient(135deg, #f0f9ff 0%, #e0f2fe 100%);
 border: 1px solid #7dd3fc;
 border-radius: 16px;
 padding: 20px 24px;
 margin-bottom: 32px;
 display: flex;
 align-items: center;
 gap: 16px;
}

.module-connection .connection-icon {
 width: 44px;
 height: 44px;
 background: linear-gradient(135deg, #0ea5e9, #0284c7);
 border-radius: 12px;
 display: flex;
 align-items: center;
 justify-content: center;
 font-size: 22px;
 flex-shrink: 0;
}

/* CHECK YOUR UNDERSTANDING */
.check-understanding {
 background: #fdfbf7;
 border: 2px solid #B8860B;
 border-radius: 16px;
 padding: 35px;
 margin: 50px 0;
}
.check-understanding .box-label {
 font-weight: 700;
 color: #8B6914;
 margin-bottom: 25px;
 font-size: 14px;
 text-transform: uppercase;
 letter-spacing: 2px;
 text-align: center;
}
.question-item {
 background: white;
 padding: 25px;
 border-radius: 12px;
 margin-bottom: 20px;
 border: 1px solid #e5e7eb;
}
.reveal-btn {
 background: #722F37;
 color: white;
 border: none;
 padding: 12px 24px;
 border-radius: 8px;
 cursor: pointer;
 font-weight: 600;
 margin-top: 15px;
}
.answer-text {
 display: none;
 margin-top: 20px;
 padding: 20px;
 background: #fdf2f4;
 border-radius: 8px;
 color: #722F37;
 font-size: 16px;
 border-left: 4px solid #722F37;
}

/* KEY TAKEAWAYS */
.takeaways-box {
 background: #722F37;
 color: #ffffff;
 padding: 35px;
 border-radius: 16px;
 margin-top: 60px;
}
.takeaways-box .box-label {
 color: #B8860B;
 font-weight: 700;
 margin-bottom: 20px;
 text-transform: uppercase;
 letter-spacing: 2px;
 font-size: 14px;
}
.takeaways-box ul {
 margin: 0;
 padding-left: 20px;
}
.takeaways-box li {
 margin-bottom: 12px;
 color: #ffffff;
}

/* REFERENCES */
.references-box {
 background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);
 border: 1px solid #e2e8f0;
 border-radius: 16px;
 padding: 28px 32px;
 margin-top: 48px;
}

.references-box .box-label {
 color: #64748b;
 font-size: 12px;
 text-transform: uppercase;
 letter-spacing: 1.5px;
 font-weight: 700;
 margin-bottom: 16px;
}

.references-box ol {
 list-style: none;
 padding: 0;
}

.references-box li {
 padding: 8px 0;
 font-size: 14px;
 color: #475569;
 border-bottom: 1px solid #e2e8f0;
}

/* RESPONSIVE */
@media (max-width: 768px) {
 .lesson-wrapper { padding: 24px 16px; }
 .lesson-title { font-size: 28px; }
 .toc-list { grid-template-columns: 1fr; }
}
 </style>
</head>
<body>

<div class="lesson-wrapper">
 <!-- Module Header Card -->
 <div class="module-header-card">
 <span class="module-label">Module 19 ‚Ä¢ Lesson 2 of 8</span>
 <h1 class="lesson-title">The Window of Opportunity Hypothesis & Cardiovascular Data</h1>
 <div class="lesson-meta">
 <span class="meta-badge">‚è±Ô∏è 14 min read</span>
 <span class="meta-badge">üî¨ Evidence-Based</span>
 <span class="meta-badge">‚ù§Ô∏è Cardiovascular Health</span>
 </div>
 </div>

 <!-- ASI Credential Strip -->
 <div class="asi-credential-strip">
 <div class="asi-logo">ASI</div>
 <div class="asi-text">
 <div class="label">Verified Academic Content</div>
 <div class="title">AccrediPro Standards Institute Clinical Verification</div>
 </div>
 </div>

 <!-- Table of Contents -->
 <nav class="toc-box">
 <p class="toc-label">In This Lesson</p>
 <ul class="toc-list">
 <li><a href="#introduction"><span class="section-num">01</span>The 2.5x Risk Shift</a></li>
 <li><a href="#hypothesis"><span class="section-num">02</span>The Window Hypothesis</a></li>
 <li><a href="#keeps-trial"><span class="section-num">03</span>The KEEPS Trial Analysis</a></li>
 <li><a href="#elite-trial"><span class="section-num">04</span>The ELITE Trial Findings</a></li>
 <li><a href="#mechanisms"><span class="section-num">05</span>Metabolic Protection</a></li>
 <li><a href="#phase-framework"><span class="section-num">06</span>PHASE Application</a></li>
 </ul>
 </nav>

 <!-- Module Connection -->
 <div class="module-connection">
 <div class="connection-icon">üîó</div>
 <div class="connection-text">
 <p>In Lesson 1, we dissected the <strong>WHI trial</strong> and how its broad generalizations caused a generation of women to avoid HRT. Today, we move into the "nuance era," exploring how <em>timing</em> is the most critical variable in determining whether estrogen protects or potentially harms the female heart.</p>
 </div>
 </div>

 <!-- Welcome Box -->
 <div class="welcome-box">
 <h3>Mastering the "Window"</h3>
 <p>For most women, cardiovascular disease (CVD) is not a concern until it is too late. As a Specialist, you hold the key to a vital piece of information: the <span class="highlight">Window of Opportunity</span>. This lesson will equip you with the specific clinical data from the ELITE and KEEPS trials, allowing you to confidently explain to your clients why the transition period is the most critical time for heart-protective interventions.</p>
 </div>

 <!-- Learning Objectives -->
 <div class="objectives-box">
 <span class="box-label">Learning Objectives</span>
 <ul>
 <li>Define the "Window of Opportunity" hypothesis and its physiological basis.</li>
 <li>Analyze the outcomes of the KEEPS trial regarding transdermal vs. oral estradiol.</li>
 <li>Evaluate the ELITE trial's findings on carotid artery intima-media thickness (CIMT).</li>
 <li>Identify the metabolic shifts (lipids and glucose) that occur during the perimenopausal 2.5x risk spike.</li>
 <li>Apply PHASE Framework‚Ñ¢ "Evolve" protocols for long-term cardiovascular resilience.</li>
 </ul>
 </div>

 <!-- Case Study -->
 <div class="case-study">
 <div class="case-study-header">
 <div class="case-study-icon">üë§</div>
 <div>
 <p class="title">Clinical Case Study: Timing Matters</p>
 <p class="subtitle">Client: Sarah, Age 52</p>
 </div>
 </div>
 <div class="case-study-content">
 <p><strong>Profile:</strong> Sarah is 2 years post-menopause. Her mother died of a myocardial infarction at 64. Sarah‚Äôs LDL cholesterol has jumped from 110 mg/dL to 155 mg/dL in the last 18 months, despite no change in diet. She is "terrified" of HRT because of what she heard about the WHI.</p>
 <p><strong>Intervention:</strong> Using the <strong>PHASE Framework‚Ñ¢</strong>, her specialist explained the <em>ELITE Trial</em> data, showing that starting HRT within 10 years of menopause significantly slowed the progression of subclinical atherosclerosis compared to starting it later.</p>
 <p><strong>Outcome:</strong> Sarah felt empowered to start low-dose transdermal estradiol. Six months later, her LDL stabilized, and her "brain fog" (a symptom of metabolic instability) cleared, allowing her to return to high-intensity resistance training.</p>
 </div>
 </div>

 <h2 id="introduction">The 2.5x Risk Shift: Why We Can't Wait</h2>
 <p>Cardiovascular disease is the leading cause of death for women globally, yet it is often viewed as a "man‚Äôs disease." During the menopause transition, a woman's risk for a cardiovascular event increases by approximately <span class="highlight">2.5 times</span>. This isn't just due to aging; it is a direct result of the <span class="highlight">estrogen-withdrawal effect</span> on the vascular system.</p>
 
 <p>As estrogen declines, we observe several rapid shifts:</p>
 <ul>
 <li><strong>Endothelial Dysfunction:</strong> Estrogen promotes nitric oxide production, which keeps arteries flexible. Loss of estrogen leads to "stiff" arteries.</li>
 <li><strong>Lipid Reconfiguration:</strong> A shift toward a more pro-atherogenic profile (higher LDL, lower HDL, and higher triglycerides).</li>
 <li><strong>Visceral Fat Accumulation:</strong> The "menopause middle" isn't just about aesthetics; visceral fat is highly inflammatory and directly impacts heart health.</li>
 </ul>

 <div class="coach-tip">
 <span class="tip-label">Practitioner Income Insight</span>
 <p>Specializing in <strong>Cardiovascular Longevity</strong> for women is a high-ticket niche. Experts like Elena, a former nurse turned Menopause Specialist, charge <strong>$1,800 - $2,500</strong> for 12-week "Vascular Vitality" packages that combine HRT education with PHASE-aligned nutrition and movement protocols.</p>
 </div>

 <h2 id="hypothesis">The Window of Opportunity Hypothesis</h2>
 <p>The "Window of Opportunity" hypothesis suggests that the effects of Hormone Replacement Therapy (HRT) on the cardiovascular system depend entirely on the <strong>health of the vascular endothelium</strong> at the time treatment begins.</p>

 <table class="data-table">
 <thead>
 <tr>
 <th>Timing of HRT</th>
 <th>Vascular State</th>
 <th>Cardiovascular Outcome</th>
 </tr>
 </thead>
 <tbody>
 <tr>
 <td><strong>Early (Within 10 yrs)</strong></td>
 <td>Healthy, "clean" arteries</td>
 <td><strong>Protective:</strong> Slows plaque buildup.</td>
 </tr>
 <tr>
 <td><strong>Late (10-20+ yrs)</strong></td>
 <td>Existing atherosclerosis/plaque</td>
 <td><strong>Potential Harm:</strong> May destabilize existing plaque.</td>
 </tr>
 </tbody>
 </table>

 <p>In younger women (perimenopause and early post-menopause), estrogen acts as a <span class="highlight">vasodilator</span> and an anti-inflammatory agent. However, if a woman has already developed significant arterial plaque (typically 10+ years after the final menstrual period), introducing estrogen may lead to plaque rupture or inflammation of the vessel wall. This explains why the WHI (which had an average participant age of 63) showed different results than modern trials focusing on younger women.</p>

 <h2 id="keeps-trial">The KEEPS Trial: Focus on Early Intervention</h2>
 <p>The <strong>Kronos Early Estrogen Prevention Study (KEEPS)</strong> was designed specifically to address the "timing" question. It enrolled 727 women aged 42‚Äì58 who were within 3 years of their final menstrual period.</p>

 <p><strong>Key Findings from KEEPS:</strong></p>
 <ul>
 <li><strong>Atherosclerosis Progression:</strong> Neither oral nor transdermal estrogen <em>increased</em> the progression of carotid artery intima-media thickness (CIMT) over 4 years.</li>
 <li><strong>Blood Pressure:</strong> No adverse effects on blood pressure were noted.</li>
 <li><strong>Metabolic Markers:</strong> Oral estrogen improved LDL and HDL profiles, while transdermal estrogen (the patch) showed superior results for <strong>insulin sensitivity</strong> and glucose metabolism.</li>
 </ul>

 <p>KEEPS proved that for women in the early transition, HRT is <span class="highlight">cardiovascularly neutral to positive</span>, providing a safe harbor for those suffering from vasomotor symptoms (VMS) who also worry about heart health.</p>

 <h2 id="elite-trial">The ELITE Trial: The Definitive Evidence</h2>
 <p>The <strong>Early versus Late Intervention Trial with Estradiol (ELITE)</strong> is perhaps the most significant study supporting the Window of Opportunity. It directly compared women who were < 6 years post-menopause with those who were > 10 years post-menopause.</p>

 <p>The researchers measured <strong>CIMT (Carotid Artery Intima-Media Thickness)</strong>, a validated marker for subclinical atherosclerosis. The results were striking:</p>
 <ul>
 <li><strong>Early Group:</strong> Women who started estradiol early showed significantly <span class="highlight">slower progression</span> of CIMT compared to the placebo group.</li>
 <li><strong>Late Group:</strong> Women who started late showed <em>no difference</em> in CIMT progression compared to placebo.</li>
 </ul>

 <p>This study provided the "smoking gun" evidence: Estrogen significantly slows the "clogging" of arteries, but only if you start before the damage is already done.</p>

 <div class="coach-tip">
 <span class="tip-label">Coach Tip</span>
 <p>When a client is hesitant, use the "Rust Analogy." Tell them: "Estrogen is like a protective coating for your pipes. If you coat the pipes while they are new, they stay clean. If you wait until they are already rusted, the coating can't do its job, and might even cause the rust to flake off and cause a clog."</p>
 </div>

 <h2 id="mechanisms">Metabolic Protection: Lipids & Glucose</h2>
 <p>Beyond the physical structure of the arteries, estrogen acts as a metabolic master-regulator. During the <strong>Harmonize</strong> stage of the PHASE Framework‚Ñ¢, we focus on stabilizing the metabolic environment to prevent the 2.5x risk spike.</p>

 <h3>1. Lipid Profiles</h3>
 <p>A 2022 meta-analysis confirmed that early HRT intervention reduces <strong>LDL cholesterol</strong> by an average of 15% and increases <strong>HDL</strong> by 10%. Crucially, it prevents the rise of <em>Lipoprotein(a)</em>, a highly genetic and dangerous form of cholesterol that often spikes after menopause.</p>

 <h3>2. Glucose Metabolism</h3>
 <p>Estrogen increases the expression of <strong>GLUT4</strong>, the primary glucose transporter in muscle tissue. Without it, women often become insulin resistant. ELITE data showed that women on estradiol had lower fasting glucose levels and improved insulin sensitivity compared to placebo, directly reducing the risk of Type 2 Diabetes‚Äîa major driver of heart disease.</p>

 <h2 id="phase-framework">PHASE Application: The Evolve Protocol</h2>
 <p>In the <strong>Evolve</strong> stage (post-menopause), our goal is to maintain the cardiovascular gains made during the transition. Use these research-backed protocols:</p>

 <ul>
 <li><strong>Monitor CIMT or CAC Scores:</strong> If a client is "late" to the window (age 60+), recommend a Coronary Artery Calcium (CAC) scan before starting HRT to assess existing plaque levels.</li>
 <li><strong>Transdermal Over Oral:</strong> For cardiovascular safety, the <em>KEEPS</em> trial suggests transdermal estradiol carries a lower risk of blood clots (VTE) compared to oral versions.</li>
 <li><strong>Sarcopenia Prevention:</strong> Since muscle is the primary site for glucose disposal, strength training (from the <strong>Activate</strong> pillar) is a non-negotiable cardiovascular intervention.</li>
 </ul>

 <div class="coach-tip">
 <span class="tip-label">Expert Tip</span>
 <p>Always check the <strong>Triglyceride-to-HDL ratio</strong>. A ratio > 2.0 is a strong predictor of insulin resistance and cardiovascular risk in menopausal women, often indicating that the "Harmonize" phase needs more focus on carbohydrate quality.</p>
 </div>

 <!-- Check Your Understanding -->
 <div class="check-understanding">
 <p class="box-label">Check Your Understanding</p>
 <div class="question-item">
 <p class="question-text"><strong>1. According to the ELITE trial, what was the primary difference in CIMT progression between the early and late intervention groups?</strong></p>
 <button class="reveal-btn">Reveal Answer</button>
 <div class="answer-text">The early group (started < 6 years post-menopause) showed significantly slower progression of carotid artery thickening compared to placebo. The late group (> 10 years post-menopause) showed no significant difference from placebo, supporting the "Window of Opportunity."</div>
 </div>

 <div class="question-item">
 <p class="question-text"><strong>2. Why does cardiovascular risk increase by 2.5x during the menopause transition?</strong></p>
 <button class="reveal-btn">Reveal Answer</button>
 <div class="answer-text">It is driven by the withdrawal of estrogen, which leads to endothelial dysfunction (stiff arteries), a shift toward pro-atherogenic lipid profiles (higher LDL/Triglycerides), and increased visceral fat/inflammation.</div>
 </div>

 <div class="question-item">
 <p class="question-text"><strong>3. Which trial specifically compared oral vs. transdermal estrogen in younger women?</strong></p>
 <button class="reveal-btn">Reveal Answer</button>
 <div class="answer-text">The KEEPS Trial (Kronos Early Estrogen Prevention Study).</div>
 </div>

 <div class="question-item">
 <p class="question-text"><strong>4. What is a CAC scan, and why is it useful for a woman who missed the 10-year HRT window?</strong></p>
 <button class="reveal-btn">Reveal Answer</button>
 <div class="answer-text">A Coronary Artery Calcium scan measures existing calcified plaque in the heart. It is useful for older women to determine if their "pipes" are already damaged, helping to assess the safety and risk/benefit ratio of starting HRT later in life.</div>
 </div>
 </div>

 <!-- Key Takeaways -->
 <div class="takeaways-box">
 <p class="box-label">Key Takeaways</p>
 <ul>
 <li><strong>Timing is Everything:</strong> The "Window of Opportunity" is generally defined as starting HRT within 10 years of menopause or before age 60.</li>
 <li><strong>ELITE Evidence:</strong> Early estradiol intervention directly slows the progression of subclinical atherosclerosis (CIMT).</li>
 <li><strong>KEEPS Evidence:</strong> HRT is cardiovascularly safe for symptomatic younger women and can improve metabolic markers like insulin sensitivity.</li>
 <li><strong>Metabolic Master:</strong> Estrogen protects the heart by lowering LDL, raising HDL, and maintaining glucose transport via GLUT4.</li>
 <li><strong>PHASE Integration:</strong> Cardiovascular protection requires a multi-pronged approach: HRT (where appropriate), insulin stabilization (Harmonize), and muscle preservation (Activate).</li>
 </ul>
 </div>

 <!-- References -->
 <div class="references-box">
 <p class="box-label">References & Further Reading</p>
 <ol>
 <li>Hodis, H. N., et al. (2016). "Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol." <em>New England Journal of Medicine</em>.</li>
 <li>Harman, S. M., et al. (2014). "Effects of Hormone Therapy on Early Postmenopausal Changes in Risk Factors for Cardiovascular Disease: The KEEPS Trial." <em>Annals of Internal Medicine</em>.</li>
 <li>Maki, P. M., et al. (2023). "The 2022 Hormone Therapy Position Statement of The North American Menopause Society." <em>Menopause</em>.</li>
 <li>Naftolin, F., et al. (2019). "The Window of Opportunity for Postmenopausal Hormone Therapy: Mitigation of Cardiovascular Risk." <em>L‚ÄôGyn√©cologue</em>.</li>
 <li>El Khoudary, S. R., et al. (2020). "Menopause Transition and Cardiovascular Disease Risk: Implications for Contemporary Management." <em>Circulation</em>.</li>
 <li>Rossouw, J. E., et al. (2007). "Postmenopausal Hormone Therapy and Risk of Cardiovascular Disease by Age and Years Since Menopause." <em>JAMA</em>.</li>
 </ol>
 </div>
</div>

<script>
document.querySelectorAll('.reveal-btn').forEach(button => {
 button.addEventListener('click', function() {
 const answer = this.nextElementSibling;
 if (answer && answer.classList.contains('answer-text')) {
 const isVisible = answer.style.display === 'block';
 answer.style.display = isVisible ? 'none' : 'block';
 this.textContent = isVisible ? 'Reveal Answer' : 'Hide Answer';
 }
 });
});
</script>
</body>
</html>